Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Intangibles (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Intangibles for 9 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 2006.23% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 2006.23% year-over-year, with the annual reading at $5.8 million for FY2025, 2006.23% up from the prior year.
  • Intangibles for Q4 2025 was $5.8 million at Gyre Therapeutics, up from $4.8 million in the prior quarter.
  • The five-year high for Intangibles was $5.8 million in Q4 2025, with the low at $184000.0 in Q3 2024.
  • Average Intangibles over 4 years is $2.4 million, with a median of $499000.0 recorded in 2022.
  • The sharpest move saw Intangibles tumbled 61.06% in 2024, then skyrocketed 2924.73% in 2025.
  • Over 4 years, Intangibles stood at $297000.0 in 2022, then skyrocketed by 136.03% to $701000.0 in 2023, then tumbled by 61.06% to $273000.0 in 2024, then soared by 2006.23% to $5.8 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $5.8 million, $4.8 million, and $5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.